Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have been assigned an average recommendation of “Moderate Buy” from the twenty-one analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating and nineteen have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $203.1667.

Several research analysts have issued reports on AXSM shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $225.00 target price on shares of Axsome Therapeutics in a report on Monday, January 5th. HC Wainwright boosted their price objective on shares of Axsome Therapeutics from $200.00 to $260.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 14th. B. Riley assumed coverage on Axsome Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 target price for the company. Finally, TD Cowen reaffirmed a “buy” rating on shares of Axsome Therapeutics in a report on Wednesday, December 31st.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

Axsome Therapeutics Trading Down 0.5%

NASDAQ AXSM opened at $185.96 on Friday. Axsome Therapeutics has a 12 month low of $86.99 and a 12 month high of $191.50. The stock has a market cap of $9.37 billion, a P/E ratio of -39.82, a P/E/G ratio of 9.80 and a beta of 0.44. The stock’s fifty day moving average price is $159.39 and its 200-day moving average price is $133.27. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The company had revenue of $170.99 million during the quarter, compared to analysts’ expectations of $162.96 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The firm’s revenue was up 63.2% on a year-over-year basis. As a group, equities analysts forecast that Axsome Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other news, Director Mark E. Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the sale, the director directly owned 10,002 shares in the company, valued at $1,652,130.36. The trade was a 78.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Nick Pizzie sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $187.92, for a total transaction of $2,255,040.00. Following the transaction, the chief financial officer directly owned 42,588 shares of the company’s stock, valued at $8,003,136.96. The trade was a 21.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 440,403 shares of company stock worth $67,191,178. Company insiders own 22.30% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC grew its holdings in shares of Axsome Therapeutics by 602.6% in the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock worth $50,000 after acquiring an additional 235 shares during the period. Stanley Laman Group Ltd. boosted its position in Axsome Therapeutics by 2.4% in the fourth quarter. Stanley Laman Group Ltd. now owns 17,918 shares of the company’s stock worth $3,273,000 after purchasing an additional 417 shares during the last quarter. Yorktown Management & Research Co Inc bought a new stake in shares of Axsome Therapeutics during the 4th quarter valued at about $310,000. Sumitomo Mitsui Trust Group Inc. purchased a new stake in shares of Axsome Therapeutics during the 4th quarter valued at about $347,000. Finally, Franklin Street Advisors Inc. NC bought a new position in shares of Axsome Therapeutics in the 4th quarter worth approximately $1,826,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.